Kenneth Toombs, a director at Vogenx, Inc., has acquired 50,000 stock options as part of his ongoing commitment to the company. This acquisition, filed on October 6, 2026, is significant as it aligns Toombs' interests with the future performance of Vogenx, a player in the pharmaceutical preparations industry.
Background
Vogenx, Inc. is a Delaware-based company operating in the pharmaceutical preparations sector, specifically categorized under SIC 2834. The company is incorporated in Delaware and has its business address in Raleigh, North Carolina. Its fiscal year ends on December 31.
What the Filing Says
The filing indicates that Toombs acquired the stock options at an exercise price of $18.23 on October 2, 2026. The options are set to vest over a three-year period in equal annual installments, contingent upon Toombs' continued service to the company. This structure incentivizes his long-term commitment to Vogenx.
Impact
This acquisition may influence various stakeholders, including Vogenx's board of directors and shareholders. As a director, Toombs' ownership of these options could affect future strategic decisions and align his interests with those of the company's investors.
What's Next
The filing does not say what happens next.
Details of the Stock Options
The stock options acquired by Toombs have an expiration date set for October 2, 2036, allowing a ten-year window for exercise after acquisition. This long-term horizon may further enhance Toombs' alignment with the company's strategic goals.
Vesting Schedule
As specified in the filing, the stock options will vest in three equal annual installments of 16,666 shares on October 2, 2027, 16,667 shares on October 2, 2028, and 16,667 shares on October 2, 2029. This staggered vesting schedule is designed to ensure that Toombs remains engaged with the company over the long term.
Ownership Structure
Following this transaction, Toombs will directly own a total of 50,000 shares of common stock, reflecting his direct ownership nature as indicated in the filing. This ownership stake may provide him with a significant voice in corporate governance matters.
Legal Representation
The filing was signed by Steven R. Delmar, who acted as Attorney-in-Fact for Kenneth Toombs, indicating that Toombs has authorized Delmar to file this report on his behalf.
Additional Information
The filing does not provide details on any previous stock option grants or other compensatory arrangements that Toombs may have with Vogenx, nor does it mention any potential conflicts of interest or other relevant disclosures that may affect his role as a director.